Medicare broker compensation varies sharply across plan types, and that gap shapes which plans retirees most often hear about during open enrollment. A typical free Medicare review ends with a recommendation for a Medicare Advantage plan that carries a $0 premium, dental coverage, and a small grocery allowance. What rarely comes up is the commission attached to that recommendation, or the alternative of Original Medicare paired with a Medigap supplement. That commission gap sits at the center of years of federal scrutiny, and it is the single mechanic that most often decides which plan a broker presents first.
What CMS Pays a Broker to Sell Each Plan
CMS sets annual Fair Market Value caps on broker compensation for Medicare Advantage and Part D plans. For 2026, the national maximum a broker can earn for enrolling a beneficiary in a Medicare Advantage plan is $694 for an initial enrollment and $347 for each renewal year. Regional caps run higher: brokers in California and New Jersey can earn up to $864 initial and $432 renewal, and those in Connecticut, Pennsylvania, and the District of Columbia earn $781 initial and $391 renewal.
A standalone Part D drug plan, by contrast, pays a national maximum of $114 for an initial enrollment. So a Medicare Advantage enrollment pays a broker roughly six times what a standalone Part D enrollment does. CMS does not set Medigap commissions; each insurer negotiates its own, typically as a percentage of premium that in most states lands well below the Medicare Advantage initial cap in year-one dollars.
Two features of this schedule stand out. First, the initial-to-renewal ratio runs 2-to-1: a broker earns twice as much to move a beneficiary into a new plan as to keep them in an existing one. Second, switching a client from one Medicare Advantage plan to another in a future enrollment period can reset the clock to the higher initial rate. Both features push compensation the same way, toward new enrollments and plan changes rather than retention or fit.
What Federal Investigators Have Found
Concerns about marketing-driven steering are not theoretical. In a March 2025 report titled Pushing Medicare Advantage on Seniors: Unraveling the Complex Network of Marketing Middlemen, Senate Finance Committee Ranking Member Ron Wyden documented rapid growth in insurers’ spending on field marketing organizations and broker commissions, alongside complaints of high-pressure sales and inappropriate plan switching. The report tied those patterns to earlier findings from the Senate Special Committee on Aging and the Finance Committee in 2008, which described deceptive MA marketing tactics, and it concluded that many of the same practices had returned in updated form.
The financial backdrop reinforces the picture. The Medicare Payment Advisory Commission estimated that the federal government paid Medicare Advantage insurers about $84 billion more in 2025 than the same beneficiaries would have cost in Traditional Medicare, a figure MedPAC projects will ease to roughly $76 billion in 2026 under a revised risk-coding model. The Joint Economic Committee traced part of that cost to beneficiaries directly: in its March 10, 2026 brief The Part B Premium Pass-Through, the JEC estimated that MA overpayments raised Part B premiums by $212 per enrollee, or $13.4 billion, in 2025, and that since 2016 they have added about $82 billion to Part B premiums, with roughly $6 billion of that burden landing on Traditional Medicare beneficiaries who never enrolled in an MA plan.
Together, the figures show a system that pays more, and pays more often, when an MA enrollment occurs, even though the schedule alone cannot tell you how any individual broker behaves.
Why the Recommendation Is Closer to Irreversible Than It Feels
Switching from Original Medicare to a $0-premium Medicare Advantage plan during open enrollment is straightforward. Switching back is much harder. Once the federal six-month Medigap open enrollment window closes, insurers in most states can medically underwrite a Medigap application and decline coverage or charge more based on health history. A handful of states, including New York, Connecticut, Massachusetts, and Maine, grant broader guaranteed-issue rights, but the federal default is one-time and narrow.
A retiree who accepts a Medicare Advantage plan whose network excludes a needed specialist may later find that the Medigap policy they would now prefer is no longer available on standard terms. The advertised in-network out-of-pocket maximum also understates the worst case: it excludes Part D drug spending and out-of-network care, so a serious illness involving specialists outside the network can push total annual costs well above the number a broker quoted at the kitchen table.
How to Tell Whether a Broker’s Recommendation Is Aligned
A few questions surface the conflict before a signature does:
- Is the broker captive or independent? A captive agent represents only one insurer’s plans. An independent broker may represent many, but their slate of contracts still determines what they can sell, and which carriers pay them the most.
- Does the recommendation compare Original Medicare plus Medigap against the Advantage plan? If the conversation skips that side-by-side, someone has already narrowed it.
- Are your current doctors and prescriptions in the proposed plan’s network and formulary, by name? A name-by-name check is the only real verification.
The State Health Insurance Assistance Program, known as SHIP, offers free one-on-one counseling from trained volunteers who earn no commission on plan selection. Each state runs its own program, and you can find a local office through shiphelp.org. A SHIP counselor can review your current plan, model the cost of switching, and explain the underwriting consequences of moving between Medicare Advantage and Medigap.
If you are weighing an annual plan change, two steps cut the risk of a steered recommendation: run the scenario past a SHIP counselor before you sign anything a broker recommends, and get it in writing whether moving to the proposed plan would block a future return to Medigap without underwriting in your state.
Top Gaining Stocks
Top Losing Stocks